ストックスクリーナーアプリを入手
2.01
3.08%
0.06
アフターアワーズ：
2.01
前日終値:
$1.95
開ける：
$1.95
24時間の取引高:
106.33K
Relative Volume:
0.08
時価総額：
$20.93M
収益：
-
当期純損益:
$-45.57M
株価収益率:
-0.319
EPS:
-6.3
ネットキャッシュフロー:
$-38.56M
1週間 パフォーマンス:
-11.06%
1か月 パフォーマンス:
-3.37%
6か月 パフォーマンス:
+47.79%
1年 パフォーマンス:
-25.56%
1日の値動き範囲:
$1.85
$2.0248
1週間の範囲:
$1.85
$2.35
52週間の値動き範囲:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
SABS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.01 | 20.30M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc (SABS) 最新ニュース
Institutional scanner results for SAB Biotherapeutics Inc. Equity WarrantQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
SAB Biotherapeutics Board Members Resign in Agreement - TipRanks
SAB Biotherapeutics reduces board size following resignations of two directors - Investing.com India
Strategies to average down on SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Will a bounce in SAB Biotherapeutics Inc. Equity Warrant offer an exit2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
Will breakout in SAB Biotherapeutics Inc. Equity Warrant lead to full recoveryJuly 2025 Review & Comprehensive Market Scan Reports - newser.com
Visual trend scoring systems applied to SAB Biotherapeutics Inc. Equity WarrantWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Can technical indicators confirm SAB Biotherapeutics Inc.’s reversal2025 Volume Leaders & Community Consensus Trade Signals - newser.com
What drives SAB Biotherapeutics Inc Equity Warrant stock priceHigh Yield Income Stocks & Explosive Capital Growth - earlytimes.in
Will SAB Biotherapeutics Inc. see short term momentum2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Using data filters to optimize entry into SAB Biotherapeutics Inc.Insider Buying & Daily Stock Trend Watchlist - newser.com
Is SAB Biotherapeutics Inc. Equity Warrant stock a buy in volatile marketsJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Tools to monitor SAB Biotherapeutics Inc. Equity Warrant recovery probabilityGold Moves & Short-Term Trading Alerts - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant stock benefit from upcoming earnings reportsWeekly Risk Report & Community Consensus Picks - newser.com
Is SAB Biotherapeutics Inc. stock bottoming out2025 Market Trends & Growth Focused Stock Pick Reports - newser.com
Can SAB Biotherapeutics Inc. stock sustain institutional interestJuly 2025 Fed Impact & High Yield Stock Recommendations - newser.com
Is SAB Biotherapeutics Inc. stock reversal real or fakeTrade Signal Summary & Growth Oriented Trading Recommendations - newser.com
Published on: 2025-09-28 22:57:55 - newser.com
Aclara Resources Inc JD1 Stock Analysis and ForecastTechnical Analysis Insights & Fast Growing Capital Growth - Early Times
What analysts say about SAB Biotherapeutics Inc stockFibonacci Retracement Levels & Affordable Market Insights - earlytimes.in
Full technical analysis of SAB Biotherapeutics Inc. stockJuly 2025 Movers & Safe Capital Investment Plans - newser.com
SAB Biotherapeutics Approves Equity Plan Amendments - MSN
SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal - Investing.com Canada
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):